CPT-11联合顺铂治疗晚期肺鳞癌20例

ClinicalStudy of CPT-11Combined with Cisplatin in The Treatment of Advanced Squamous Cell Carcinoma of Lung

目的:观察CPT-11联合顺铂治疗晚期肺鳞癌的临床疗效。方法:选取2014年1月至2016年7月于就诊的晚期肺鳞癌患者40例,根据治疗方式的不同,分为A组(20例)与B组(20例),A组患者采用IP方案(CPT-11+顺铂)化疗,B组患者采用GP方案(吉西他滨+顺铂)化疗,比较两组患者的治疗效果。结果:A组患者的疾病控制率显著高于B组(P<0.05);A组患者的PFS显著多于B组(P<0.05);两组患者的毒副反应发生率对比差异无统计学意义(P>0.05)。结论:CPT-11联合顺铂治疗晚期肺鳞癌的疗效良好,毒副反应可耐受,且能够有效延长患者的生存时间,具有临床推广使用价值。

Objective:To observe and analyze the clinical efficacy of CPT-11 combined with cisplatin in the treatment of advanced squamous cell carcinoma of the lung.Methods:40patients with advanced lung squamous cell carcinoma from January 2014 to July 2016 in our hospital,according to different treatment methods,were divided into A group(n =20)and B group(n =20),A group were treated with the IP regimen(CPT-11+ cisplatin)chemotherapy,group B were treated with the GP regimen(gemcitabine+ cisplatin)chemotherapy,contrast two groups of patients with therapeutic effect.Results:A group of patients with the disease control rate was significantly higher than that of B group(P <0.05);A group of patients with PFS was significantly higher than in group B(P<0.05);adverse reaction rate in two groups compared no significant difference,no statistical significance(P>0.05).Conclusion:CPT-11 combined with cisplatin in the treatment of advanced squamous cell lung cancer has a good curative effect,toxicity and side effects can be tolerated,and can effectively prolong the survival time of patients with clinical use value.